Humanigen Inc. [NASDAQ: HGEN] price plunged by -8.98 percent to reach at -$0.02. The company report on September 12, 2022 that Humanigen and SAHMRI Announce Expansion of the PREACH-M Study of Lenzilumab in CMML.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
Additional Clinical Sites Expected to Enroll CMML Patients in Australia.
Short Hills, New Jersey and Adelaide, South Australia–(Newsfile Corp. – September 12, 2022) – Humanigen, Inc. (Nasdaq: HGEN), Humanigen Australia Pty Ltd, (“Humanigen”) and the South Australian Health and Medical Research Institute (“SAHMRI”) today announced an expansion of the ongoing development Precision Approach to Chronic Myelomonocytic Leukemia (“PREACH-M”) study of lenzilumab in chronic myelomonocytic leukemia (“CMML”), a rare blood cancer, in patients with NRAS, KRAS, and CBL genetic mutations. The PREACH-M study will expand from the first two sites at the Royal Adelaide Hospital in Adelaide, Southern Australia and Austin Health-Austin Hospital in Heidelberg, Victoria to add up to 6 additional sites; one in Queensland, one in Western Australia, two sites in New South Wales, a site in Tasmania, and options being explored for an additional site in New Zealand.
A sum of 4081699 shares traded at recent session while its average daily volume was at 9.29M shares. Humanigen Inc. shares reached a high of $0.181 and dropped to a low of $0.1612 until finishing in the latest session at $0.16.
The one-year HGEN stock forecast points to a potential upside of 95.82. The average equity rating for HGEN stock is currently 3.20, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Humanigen Inc. [HGEN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HGEN shares is $3.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HGEN stock is a recommendation set at 3.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH Capital have made an estimate for Humanigen Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 13, 2022. The new note on the price target was released on July 13, 2022, representing the official price target for Humanigen Inc. stock. Previously, the target price had yet another drop from $30 to $2, while Cantor Fitzgerald kept a Neutral rating on HGEN stock.
The Average True Range (ATR) for Humanigen Inc. is set at 0.02, with the Price to Sales ratio for HGEN stock in the period of the last 12 months amounting to 4.47.
HGEN Stock Performance Analysis:
Humanigen Inc. [HGEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -24.46. With this latest performance, HGEN shares dropped by -46.20% in over the last four-week period, additionally sinking by -95.70% over the last 6 months – not to mention a drop of -97.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HGEN stock in for the last two-week period is set at 24.69, with the RSI for the last a single of trading hit 18.63, and the three-weeks RSI is set at 29.49 for Humanigen Inc. [HGEN]. The present Moving Average for the last 50 days of trading for this stock 0.3284, while it was recorded at 0.1851 for the last single week of trading, and 2.1042 for the last 200 days.
Insight into Humanigen Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Humanigen Inc. [HGEN] shares currently have an operating margin of -6474.88. Humanigen Inc.’s Net Margin is presently recorded at -6582.73.
Return on Equity for this stock declined to -2,165.43, with Return on Assets sitting at -339.62.
Humanigen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.60 and a Current Ratio set at 0.60.
HGEN Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for HGEN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Humanigen Inc. go to 12.50%.
Humanigen Inc. [HGEN] Insider Position Details
There are presently around $4 million, or 21.30% of HGEN stock, in the hands of institutional investors. The top three institutional holders of HGEN stocks are: VALIANT CAPITAL MANAGEMENT, L.P. with ownership of 6,888,607, which is approximately 0% of the company’s market cap and around 13.74% of the total institutional ownership; MURCHINSON LTD., holding 5,250,000 shares of the stock with an approximate value of $0.85 million in HGEN stocks shares; and VANGUARD GROUP INC, currently with $0.4 million in HGEN stock with ownership of nearly 1.062% of the company’s market capitalization.
Positions in Humanigen Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 29 institutional holders increased their position in Humanigen Inc. [NASDAQ:HGEN] by around 1,819,751 shares. Additionally, 54 investors decreased positions by around 8,479,030 shares, while 15 investors held positions by with 11,775,225 shares. The mentioned changes placed institutional holdings at 22,074,006 shares, according to the latest SEC report filing. HGEN stock had 16 new institutional investments in for a total of 978,436 shares, while 31 institutional investors sold positions of 2,014,516 shares during the same period.